APA (7th ed.) Citation

L, C., A, F., V, C., M, D., M, B., C, C., . . . SM, P. (2025). CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. Journal of experimental & clinical cancer research : CR, 44(1), 19. https://doi.org/10.1186/s13046-025-03276-z

Chicago Style (17th ed.) Citation

L, Castagnoli, et al. "CD36 Enrichment in HER2-positive Mesenchymal Stem Cells Drives Therapy Refractoriness in Breast Cancer." Journal of Experimental & Clinical Cancer Research : CR 44, no. 1 (2025): 19. https://doi.org/10.1186/s13046-025-03276-z.

MLA (9th ed.) Citation

L, Castagnoli, et al. "CD36 Enrichment in HER2-positive Mesenchymal Stem Cells Drives Therapy Refractoriness in Breast Cancer." Journal of Experimental & Clinical Cancer Research : CR, vol. 44, no. 1, 2025, p. 19, https://doi.org/10.1186/s13046-025-03276-z.